Aromatase inhibitors as adjuvant therapy in breast cancer

ONCOLOGY

Volumn 17, Issue 3, 2003, Pages

  Visvanathan, Kala ^a   Davidson, Nancy E ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CLINICAL TRIAL; FEMALE; HUMAN; REVIEW;

AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; FEMALE; HUMANS; NITRILES; TRIAZOLES;

EID: 0038620410     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Ries L, Kosary C, Hankey B (eds): SEER Cancer Statistics Review, 1973-1996, National Cancer Institute NIH Pub No. 99-2789. Be- thesda, Md, National Cancer Institute, 1996.
2. American Cancer Society: Breast Cancer Facts and Figures 2001-2002. Atlanta, American Cancer Society, 2002.
3. Goss PE, Strasser K: Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19:881-894, 2001.
4. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618, 1998.
5. The ATAC Trialists Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002.
6. Clemons M, Goss P: Estrogen and the risk of breast cancer. N Engl J Med 344:276-285, 2001.
7. Gruber CJ, Tschugguel W, Schneeberger C, et al: Production and actions of estrogens. N Engl J Med 346:340-352, 2002.
8. Boeddinghaus IM, Dowsett M: Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors. J Steroid Biochem Mol Biol 79:85-91, 2001.
9. Lonning PE, Geisler J, Johannessen DC, et al: Pharmacokinetics and metabolism of formestane in breast cancer patients. J Steroid Biochem Mol Biol 77:39-47, 2001.
10. Gale KE, Andersen JW, Tormey DC, et al: Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen. Cancer 73:354-361, 1994.
11. Buzdar A, Howell A: Advances in aromatase inhibition: Clinical efficacy and tolera- bility in the treatment of breast cancer. Clin Cancer Res 7:2620-2635, 2001.
12. Howell A, Downey S, Anderson E: New endocrine therapies for breast cancer. Eur J Cancer 32A:576-588, 1996.
13. Dowsett M, Jones A, Johnston SR, et al: In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1:1511-1515, 1995.
14. Geisler J, King N, Anker G, etal: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4:2089-2093, 1998.
15. MacNeill FA, Jones AL, Jacobs S, et al: The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 66:692-697, 1992.
16. Stein RC, Dowsett M, Hedley A, et al: The clinical and endocrine effects of 4-hy- droxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 62:679-683, 1990.
17. Wouters W, De Coster R, Tuman RW, et al: Aromatase inhibition by R 76713: Experimental and clinical pharmacology. J Steroid Biochem 34:427-430, 1989.
18. di Salle E, Ornati G, Giudici D: Exemestane (FCE24304); a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 43:143, 1992.
19. Lien EA, Anker G, Lonning PE, et al: Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res 50:5851-5857, 1990.
20. Dowsett M, Pfister CU, Johnston SR, et al: Pharmacokinetic interaction between letrozole and tamoxifen in postmenopausal patients with advanced breast cancer. The Breast 6:245, 1997.
21. Ingle JN, Suman VJ, Jordan VC, et al: Combinational hormonal therapy involving aromatase inhibitors in the management of women with breast cancer. Endocr Relat Cancer 6:267, 1999.
22. Dowsett M, Tobias JS, Howell A, et al: The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. Br J Cancer 79:311-315, 1999.
23. The ATAC Trialists Group: Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: A sub-protocol of the "Arimi- dex and tamoxifen alone or in combination" (ATAC) trial. Br J Cancer 85:317-324, 2001.
24. Kaufmann M, Bajetta E, Dirix LY, et al: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18:1399-1411, 2000.
25. Jonat'W, Howell A, Blomqvist C, et al: A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A:404-412, 1996.
26. Dombernowsky P, Smith I, Falkson G, et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998.
27. Buzdar AU, Jones SE, Vogel CL, et al: A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 79:730-739, 1997.
28. Buzdar AU, Jonat W, Howell A, et al: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83:1142-1152, 1998.
29. Buzdar A, Douma J, Davidson N, et al: Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19:3357-3366, 2001.
30. Gershanovich M, Chaudri HA, Campos D, et al:-Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 9:639-645, 1998.
31. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first- line therapy for advanced breast cancer in post- menopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18:3758-3767, 2000.
32. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001.
33. Bonneterre J, Thurlimann B, Robertson JF, et al: Anastrozole versus tamoxifen as first- line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18:3748-3757, 2000.
34. Geisler J, Haynes B, Anker G, et al: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20:751-757, 2002.
35. Rose C, Vtoraya O, Pluzanska A, et al: Letrozole (Femara) vs anastrozole (Arimidex): Second-line treatment in postmenopausal worn-' en with advanced breast cancer (abstract 131). ProcAm Soc Clin Oncol 21:34a, 2002.
36. Lonning PE, Bajetta E, Murray R, et al: Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial. J Clin Oncol 18:2234-2244, 2000.
37. Jones AL, Powles TJ, Law M, et al: Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: Analysis at 8 years. J Clin Oncol 10:1547-1552, 1992.
38. Boccardo F, Rubagotti A, Amoroso D, et al: Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian cooperative study. J Clin Oncol 19:4209-4215, 2001.
39. Osborne CK, Hobbs K, Clark GM: Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45:584-590, 1985.
40. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, .1998.
41. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node- negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989.
42. Miller WR, Telford J, Love C, et al: Effects of letrozole as primary medical therapy on in situ estrogen synthesis and endogenous levels within the breast. The Breast 7:276, 1998.
43. Geisler J, Bernsten L, Ottestad L, et al: Comparison of the effects of neoadjuvant "Arimidex" (anastrozole) on plasma "and intra- tumor tissue estrogen levels in postmenopausal breast cancer patients. The Breast 8:241, 1999.
44. Dixon JM, Love CD, Renshaw L, et al: Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocr Relat Cancer 6:227-230, 1999.
45. 45.Dixon JM, Renshaw L, Bellamy C, et al: The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal worn-en with breast cancer: A randomized, double- blind, single-center study. Clin Cancer Res 6:2229-2235, 2000.
46. Dixon MJ, Renshaw C, Bellamy DA, et al: "Arimidex" as neoadjuvant therapy causes large reductions in tumor volume in postmenopausal women with large operable breast cancers (abstract 345). Proc Am Soc Clin Oncol 18:92a, 1999.
47. Miller WR, Dixon JM: Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 9:9-15, 2002.
48. Dixon JM, Love CDB, Tucker C, et al: Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Eur J Cancer 34:S13, 1998.
49. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001.
50. The National Institutes of Health Consensus Development Conference: Adjuvant Therapy for Breast Cancer. Bethesda, Md, Nov 1-3, 2000. J Natl Cancer Inst Monogr, pp 1- 152, 2001.
51. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19:3817-3827, 2001.
52. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: Status report 2002. J Clin Oncol 20:1-15, 2002.
53. Harper-Wynne C, Ross G, Sacks N, et al: Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: A pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 11:614-621, 2002.
54. Dowsett M: Theoretical considerations for the ideal aromatase inhibitor. Breast Cancer Res Treat 49(suppl 1):S39-S44, 1998.